Decreased expression of long noncoding RNA XLOC_013703 promotes cell growth via NF‐κB pathway in multiple myeloma

Long noncoding RNAs (lncRNAs) are dysregulated in cancer and involved in oncogenic or tumor inhibitory processes. The aim of the study was to investigate the expression pattern of lncRNA XLOC_013703 in multiple myeloma (MM) and to evaluate its biological role and potential significance. We found that XLOC_013703 was significantly decreased in CD138 positive plasma cells and serum of MM patients compared to normal controls, and the decreased XLOC_013703 expression was correlated with β2‐MG, serum‐free light chain (s‐FLC) and revised international staging system. RNA‐fluorescence in situ hybridization results revealed that XLOC_013703 was distributed both in the nucleus and in the cytoplasm of MM cells including H929, RPMI8226, and U266. Overexpression of XLOC_013703 inhibited the proliferation of U266 cells and blocked the cell cycle in G1 stage, thus contributing to MM cell apoptosis. By contrast, knockdown of XLOC_013703 promoted the growth of H929 cells. Western blot analysis confirmed that the expression of p‐IκBα and nuclear P65 was substantially increased in shRNA transfection groups compared to control groups, whereas overexpression of XLOC_013703 reduced these expressions. In conclusion, we confirmed that the decreased expression of a novel lncRNA, XLOC_013703, in MM. XLOC_013703 was involved in MM cell survival and proliferation via nuclear factor‐κB pathway which represents a potential therapeutic target for MM. © 2019 IUBMB Life, 71(9):1240–1251, 2019

[1]  L. Kristensen,et al.  Long Non-Coding RNAs Guide the Fine-Tuning of Gene Regulation in B-Cell Development and Malignancy , 2018, International journal of molecular sciences.

[2]  Hua-long Yu,et al.  Overexpression of miR-21-5p promotes proliferation and invasion of colon adenocarcinoma cells through targeting CHL1 , 2018, Molecular medicine.

[3]  Hua-long Yu,et al.  Overexpression of miR-21-5p promotes proliferation and invasion of colon adenocarcinoma cells through targeting CHL1 , 2018, Molecular Medicine.

[4]  P. L. Bergsagel,et al.  Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement , 2018, Bone Marrow Transplantation.

[5]  A. Neri,et al.  Long Non-Coding RNAs in Multiple Myeloma , 2018, Genes.

[6]  Suying Wang,et al.  Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3 , 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[7]  Ning Zhang,et al.  Knockdown of long non-coding RNA H19 inhibits multiple myeloma cell growth via NF-κB pathway , 2017, Scientific Reports.

[8]  K. Kimura,et al.  Long non‐coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma , 2017, British journal of haematology.

[9]  Hanmei Xu,et al.  Tumor-related interleukins: old validated targets for new anti-cancer drug development , 2017, Molecular Cancer.

[10]  Y. Kondo,et al.  Long non‐coding RNAs as an epigenetic regulator in human cancers , 2017, Cancer science.

[11]  J. Tu,et al.  Identification of Circulating Long Noncoding RNA HOTAIR as a Novel Biomarker for Diagnosis and Monitoring of Non–Small Cell Lung Cancer , 2017, Technology in cancer research & treatment.

[12]  D. Hao,et al.  Long Noncoding RNA CRNDE Promotes Multiple Myeloma Cell Growth by Suppressing miR-451. , 2017, Oncology research.

[13]  Huan Yao,et al.  LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma , 2017, Cell Death & Disease.

[14]  V. Imbert,et al.  NF-κB in Hematological Malignancies , 2017, Biomedicines.

[15]  A. Hu,et al.  Potential prognostic long non-coding RNA identification and their validation in predicting survival of patients with multiple myeloma , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[16]  C. Hofmeister,et al.  Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  S. Ševčíková,et al.  Deregulated expression of long non‐coding RNA UCA1 in multiple myeloma , 2017, European journal of haematology.

[18]  H. Goldschmidt,et al.  Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.

[19]  Xin Zhou,et al.  Circulating long noncoding RNA GAS5 as a potential biomarker in breast cancer for assessing the surgical effects , 2016, Tumor Biology.

[20]  Ping Chen,et al.  Upregulation of lncRNA MEG3 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells From Multiple Myeloma Patients By Targeting BMP4 Transcription , 2015, Stem cells.

[21]  R. Gregory,et al.  MicroRNA biogenesis pathways in cancer , 2015, Nature Reviews Cancer.

[22]  Fei Luo,et al.  PSMB4 promotes multiple myeloma cell growth by activating NF-κB-miR-21 signaling. , 2015, Biochemical and biophysical research communications.

[23]  Jan-Gowth Chang,et al.  MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression , 2014, BMC Cancer.

[24]  Subrata Sen,et al.  Tumor-Associated Circulating MicroRNAs as Biomarkers of Cancer , 2014, Molecules.

[25]  Cheryl D. Helgason,et al.  The non-coding transcriptome as a dynamic regulator of cancer metastasis , 2013, Cancer and Metastasis Reviews.

[26]  J. Schmid,et al.  The complexity of NF-κB signaling in inflammation and cancer , 2013, Molecular Cancer.

[27]  N. Munshi,et al.  Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth , 2013, Clinical Cancer Research.

[28]  D. Glavač,et al.  Long Non-Coding RNA in Cancer , 2013, International journal of molecular sciences.

[29]  Yi Liu,et al.  miR-21 modulates cell apoptosis by targeting multiple genes in renal cell carcinoma. , 2011, Urology.

[30]  J. Fei,et al.  Antisense oligonucleotide against miR-21 inhibits migration and induces apoptosis in leukemic K562 cells , 2010, Leukemia & lymphoma.

[31]  Gabriele Sales,et al.  Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. , 2009, Blood.

[32]  Jörg Hackermüller,et al.  Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. , 2007, Blood.

[33]  C. Waes Nuclear Factor-κB in Development, Prevention, and Therapy of Cancer , 2007 .

[34]  Marco Pellegrini,et al.  Interplay Between Long Noncoding RNAs and MicroRNAs in Cancer. , 2018, Methods in molecular biology.

[35]  S. Abolmaali,et al.  miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance. , 2017, Current gene therapy.

[36]  S. Ju,et al.  Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum. , 2017, Cancer biomarkers : section A of Disease markers.

[37]  P. Sonneveld,et al.  Multiple myeloma , 2017, Nature Reviews Disease Primers.

[38]  C. Van Waes Nuclear factor-kappaB in development, prevention, and therapy of cancer. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.